In the lead up to World IBD Day, this coming Sunday, 19th May, PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
The month of May marks two very important days in the IBD calendar - Crohn's and Colitis Awareness Month, which takes place throughout May and World IBD Day, which is being held this Sunday, 19 May. Both events are designed to raise awareness for Crohn's disease and Ulcerative colitis, and show support to the 10 million people worldwide who live with IBD.
While in Sydney last month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Anna Napoli at Finance News Network, Australia's largest provider of online business and finance news.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st March 2019. The Company's cash plus term deposits at the end of the quarter stood at $6.4m, incorporating receipt of the 2017-2018 $1.249m R&D tax refund which was received on 14th January 2019. On 31st March 2019, the Company had cash at bank of $1,395,664 and $5,050,000 in term deposits.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of John Chiplin, PhD and Alan W. Dunton, M.D. to its Board of Directors, effective 29 April 2019 as independent, Non-Executive Directors.
While in Sydney earlier this month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.
